Corvus Pharmaceuticals, Inc. (CRVS) vs Jade Biosciences, Inc. (JBIO)
A side-by-side comparison of Corvus Pharmaceuticals, Inc. and Jade Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CRVS
Corvus Pharmaceuticals, Inc.
$10.28HealthcareDelayed quote: Oct 6, 2026, 10:15 AM EDT
JBIO
Jade Biosciences, Inc.
$13.33HealthcareDelayed quote: Oct 6, 2026, 10:14 AM EDT
Total return — CRVS vs JBIO
growth of $100 · dividends reinvested · last 5yCRVS +296.3% (+31.7%/yr)JBIO -97.8% (-53.5%/yr)CRVS compounded faster over this window
Log scale — wide-divergence pair
CRVS JBIO
CRVS vs JBIO: by the numbers
- •CRVS is the larger company ($864M vs $811M market cap).
Metrics side by side
Valuation
| Metric | CRVS | JBIO |
|---|---|---|
| P/B ratio | 3.84 | 1.84 |
Profitability
| Metric | CRVS | JBIO |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -24.02% | -34.83% |
| ROIC | -25.25% | -37.39% |
Growth (annualized)
| Metric | CRVS | JBIO |
|---|---|---|
| Total return CAGR (5Y) | 17.88% | -52.65% |
Frequently asked
- How have CRVS and JBIO total returns compared?
- Over the past 5 years, CRVS delivered 17.88% and JBIO delivered -52.65% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.